Compare
TransMedics Group, Inc. vs InMode Ltd. vs Conmed Corp vs LivaNova PLC
| Latest fiscal year | TransMedics Group, Inc. TMDX | InMode Ltd. INMD | Conmed Corp CNMD | LivaNova PLC LIVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $605.49M | $370.50M | $1.37B | $1.39B |
| Revenue growth (YoY) | +37.1% | -6.2% | +5.2% | +10.7% |
| Gross margin | 59.9% | 78.5% | 54.6% | 67.7% (computed) |
| Operating margin | 17.9% | 23.0% | 7.5% | 14.4% |
| Net margin | 31.4% | 25.3% | 3.4% | -17.5% |
| Net income | $190.29M | $93.83M | $47.05M | -$242.47M |
| EPS (Diluted) | $4.87 | $1.43 | $1.51 | -$4.45 |
| Operating cash flow | $192.84M | $85.26M | $170.69M | $254.34M |
| Free cash flow | $133.59M | $84.28M | $150.88M | $173.29M |
| Cash & equivalents | n/a | $302.54M | n/a | $635.55M |
| Total assets | $1.07B | $766.43M | $2.33B | $2.61B |
| Total liabilities | $595.27M | $83.23M | $1.29B | $1.41B |
| Shareholders' equity | $473.10M | $683.20M | $1.03B | $1.20B |
| Return on year-end equity | 40.2% | 13.7% | 4.6% | -20.2% |
| Shares outstanding | 34.27M | 63.36M | n/a | 54.65M |
Revenue, most recent five fiscal years
| Fiscal year | TransMedics Group, Inc. | InMode Ltd. | Conmed Corp | LivaNova PLC |
|---|---|---|---|---|
| Latest | $605.49M Ended 2025-12-31 | $370.50M Ended 2025-12-31 | $1.37B Ended 2025-12-31 | $1.39B Ended 2025-12-31 |
| 1 year earlier | $441.54M Ended 2024-12-31 | $394.82M Ended 2024-12-31 | $1.31B Ended 2024-12-31 | $1.25B Ended 2024-12-31 |
| 2 years earlier | $241.62M Ended 2023-12-31 | $492.05M Ended 2023-12-31 | $1.24B Ended 2023-12-31 | $1.15B Ended 2023-12-31 |
| 3 years earlier | $93.46M Ended 2022-12-31 | $454.27M Ended 2022-12-31 | $1.05B Ended 2022-12-31 | $1.02B Ended 2022-12-31 |
| 4 years earlier | $30.26M Ended 2021-12-31 | $357.56M Ended 2021-12-31 | $1.01B Ended 2021-12-31 | $1.04B Ended 2021-12-31 |